AIM-HIGH: ATHEROSCLEROSIS INTERVENTIONIN MATABOLIC SYNDROME WITH LOW HDL/HIGH

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。AIM-HIGH是一项多中心、前瞻性、随机、双盲、平行组、活跃的比较试验，比较辛伐他汀（他汀单药治疗）与缓释烟酸加辛伐他汀（联合治疗）在已确定血管疾病（即，那些有10年>=20%的事件风险）和动脉粥样硬化性血脂异常（低HDL-C和高甘油三酯）的高危患者中的疗效。AIM-HIGH的假设是，当用于二级预防时，联合抗血脂异常治疗将优于单独他汀类药物治疗，以减少有血管疾病和动脉粥样硬化性血脂异常患者的长期临床事件。潜在的合格参与者必须满足以下一个或多个已确定的血管疾病标准。有冠状动脉疾病（CAD）、有脑血管疾病或有症状的PAD。在3-5年的随访中，该研究将比较他汀类药物单药治疗与联合治疗在同等治疗LDL-C水平下的疗效和安全性，以降低伴有动脉粥样硬化性血脂异常（低HDL-C和高甘油三酯）的血管疾病患者的临床事件或高风险NSTE（急性冠脉综合征）住院的风险。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. AIM-HIGH is a multicenter, prospective, randomized, double-blind, parallel-group, active comparator trial of simvastatin (statin monotherapy) versus extended-release niacin plus simvastatin (combination therapy) in high-risk patients with established vascular disease (i.e., those who have a 10-year risk of an event of >=20%) and atherogenic dyslipidemia (low HDL-C and high triglycerides). The hypothesis of AIM-HIGH is that combination anti-dyslipidemic therapy will be superior to statin monotherapy alone when used as secondary prevention in reducing long-term clinical events in patients with documented vascular disease and atherogenic dyslipidemia. Potentially eligible participants must meet one or more of the following criteria for established vascular disease. Documented coronary artery disease (CAD), documented cerebrovascular disease, or documented symptomatic PAD. During a 3-5 year follow-up, the study will compare efficacy and safety of statin monotherapy versus combination therapy at comparable levels of on-treatment LDL-C, to reduce the risk for clinical events or hospitalization for high-risk NSTE acute coronary syndrome) in vascular disease patients with atherogenic dyslipidemia (low HDL-C and high triglycerides).